This week’s key IPO results spotlight Roche’s India growth, Abbott’s nutrition spin-off, Bajaj Healthcare’s strong Q2, and Moderna-Merck’s cancer vaccine breakthrough.
India’s 30% anti-cancer drug margin cap targets lower cancer medicine prices, promising patient savings while reshaping pharmaceutical and hospital economics.
The Zydus drug recall affects 70,776 injectable vials in the US after the medicine failed impurity and degradation specifications.
The FDA clears a lower-cost generic HRT patch from Zydus and approves AstraZeneca’s Ultomiris for adults with IgA nephropathy, expanding menopause care and kidney disease treatment options.
Sanofi's Qfitlia approval puts haemophilia prophylaxis in India in focus as research highlights gaps in preventive treatment.
Toripalimab's expanded use in India brings real-world evidence into focus, with a multicentre study examining treatment outcomes across PD-L1 subgroups.
GSK’s Hibsago becomes the first ASO approved for chronic hepatitis B, offering patients a new treatment approach for sustained viral control.
Fake medicine billing allegations in Lucknow highlight gaps in pharmaceutical distribution, invoice verification, and drug traceability.
Eli Lilly's Foundayo pill gains EU regulatory backing, highlighting its flexible dosing without food or water restrictions.
The Centre’s pharma push strengthens stent safety, expands clinical trial sites beyond metros and advances emergency care on Maharashtra highways.
.jpg)
, CDSCO.jpg)
